AU2002305323A1 - Fused heterocyclic compounds - Google Patents

Fused heterocyclic compounds

Info

Publication number
AU2002305323A1
AU2002305323A1 AU2002305323A AU2002305323A AU2002305323A1 AU 2002305323 A1 AU2002305323 A1 AU 2002305323A1 AU 2002305323 A AU2002305323 A AU 2002305323A AU 2002305323 A AU2002305323 A AU 2002305323A AU 2002305323 A1 AU2002305323 A1 AU 2002305323A1
Authority
AU
Australia
Prior art keywords
heterocyclic compounds
fused heterocyclic
prevention
bond
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002305323A
Other languages
English (en)
Inventor
Xiaoqi Chen
Kang Dai
Pingchen Fan
Shugui Huang
Leping Li
Jeffrey Thomas Mihalic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of AU2002305323A1 publication Critical patent/AU2002305323A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002305323A 2001-05-04 2002-05-03 Fused heterocyclic compounds Abandoned AU2002305323A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28866501P 2001-05-04 2001-05-04
US60/288,665 2001-05-04
PCT/US2002/013856 WO2002089729A2 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Publications (1)

Publication Number Publication Date
AU2002305323A1 true AU2002305323A1 (en) 2002-11-18

Family

ID=23108101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002305323A Abandoned AU2002305323A1 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Country Status (9)

Country Link
US (1) US6858619B2 (https=)
EP (1) EP1392298B1 (https=)
JP (1) JP2004529161A (https=)
AT (1) ATE422887T1 (https=)
AU (1) AU2002305323A1 (https=)
CA (1) CA2446351A1 (https=)
DE (1) DE60231202D1 (https=)
ES (1) ES2319619T3 (https=)
WO (1) WO2002089729A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
US6858619B2 (en) 2001-05-04 2005-02-22 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
CA2468159A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CN101134757A (zh) 2002-11-06 2008-03-05 安姆根有限公司 稠合杂环化合物
EP1595867A4 (en) * 2003-02-10 2008-05-21 Banyu Pharma Co Ltd PIPERIDINE DERIVATIVES AS AN ACTIVE ANTAGONIST AT THE RECIPE OF MELANIN CONCENTRATING HORMONE
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE429428T1 (de) 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
EP2668191A4 (en) 2011-01-19 2014-08-20 Albany Molecular Res Inc BENZOFURO- [3,2-C-] PYRIDINES AND RELATED ANALOGS AS SEROTONIN-SUBTYPE-6 (5-HT6) MODULATORS FOR THE TREATMENT OF ADIPOSITAS, METABOLISM SYNDROME, COGNITION AND SCHIZOPHRENIA
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US20150051220A1 (en) * 2012-03-16 2015-02-19 Glucox Biotech Ab Compounds for use in therapy
JP6274384B2 (ja) * 2012-04-27 2018-02-07 Nok株式会社 メタルガスケット及びその製造方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
CA2112744A1 (en) * 1991-07-05 1993-01-21 Vittorrio Vecchietti Hydroisoquinoline derivatives
KR100301093B1 (ko) 1992-09-29 2001-10-22 히라이 가쯔히꼬 인돌유도체,그제조방법및그의약용도
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
AU739367B2 (en) 1997-01-16 2001-10-11 Toray Industries, Inc. Indolomorphinan derivative and agent for curing and preventing cerebral disorder
WO2000021169A1 (en) 1998-10-07 2000-04-13 Sharp Kabushiki Kaisha Semiconductor laser
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
EP1153932A1 (en) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
WO2002002744A2 (en) 2000-07-05 2002-01-10 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
DE60143525D1 (de) 2000-07-05 2011-01-05 Takeda Pharmaceutical Verfahren zum screenen von mhc-rezeptorantagonisten oder -agonisten
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
CN1469876A (zh) 2000-10-20 2004-01-21 �Ʒ� α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
JP4025200B2 (ja) 2000-12-22 2007-12-19 シェーリング コーポレイション ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
IL157456A0 (en) 2001-03-21 2004-03-28 Pharmacopeia Inc Pharmacopeia Aryl and biaryl compounds having mch modulatory activity
ATE460163T1 (de) 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
US6858619B2 (en) 2001-05-04 2005-02-22 Amgen Inc. Fused heterocyclic compounds
CA2448080A1 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues

Also Published As

Publication number Publication date
EP1392298B1 (en) 2009-02-18
EP1392298A4 (en) 2005-05-25
JP2004529161A (ja) 2004-09-24
CA2446351A1 (en) 2002-11-14
WO2002089729A2 (en) 2002-11-14
ES2319619T3 (es) 2009-05-11
EP1392298A2 (en) 2004-03-03
ATE422887T1 (de) 2009-03-15
US20030023085A1 (en) 2003-01-30
US6858619B2 (en) 2005-02-22
DE60231202D1 (de) 2009-04-02
WO2002089729A3 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002305323A1 (en) Fused heterocyclic compounds
AU2003303210A1 (en) Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
ATE340796T1 (de) Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
AU6226494A (en) Spiroazacyclic derivatives as substance p antagonists
WO2003028641A3 (en) Mch receptor antagonists
HUP0100266A2 (hu) NMDA-receptor-antagonista hatású 1-aminoalkilciklohexánszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és előállításaik
CA2503767A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
MA28111A1 (fr) Derives des
AU2002368152A1 (en) 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
MX2007011848A (es) Antagonistas del receptor de procineticina i.
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
AU2002353286A1 (en) 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) Flavaxate derivatives as muscarinic receptor antagonists
NZ514696A (en) IL-8 receptor antagonists
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
WO2000068209A3 (en) 1,5-benzodiazepine derivatives as cck-a receptor agonists
ZA200604748B (en) Novel indeno[2,1A]indenes and isoindol[2,1-A]indoles
WO2001032647A3 (en) Benz`f!indoles for use in the treatment of 5ht receptor related disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase